ESPE Abstracts

Background: Micropenis may result from different aetiology and therapy data are still scarce.

Objective and hypotheses: To investigate the effect and safety of dihydrotestosterone transdermal gel in children with micropenis.

Method: Totally 23 agnogenic micropenis children with 46,XY karyotype were recruited to participate a perspective study. SRY, AR and SRD5A2 gene were sequenced. 2.5% DHT gel was applied individually based on the serum DHT level for at least three or six months. The changes of stretched penile length (SPL), serum biochemical indexes including sex hormone profile, height, weight and bone age were evaluated.

Results: There were two patients with AR mutation and five patients with SRD5A2 mutation. The average stretched penile length of 23 participants was 1.68±0.6 cm prior the treatment and the ΔPL-SDS was −1.13±0.47 cm after 6 months therapy. 61% patients reached the standard (>2.5 SDS), 13% withdrawal the medication. Hepatorenal function, CBC, height, weight, bone age and testis volume analysis showed no statistical difference compared with the data prior the treatment at 1, 3, 6 months after therapy.

Conclusion: Three to six months’ small dose of DHT therapy in micropenis children resulted in significant improvement of penis growth without evident side effects.